Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00006291
First received: September 22, 2000
Last updated: May 17, 2012
Last verified: May 2012
  Purpose

The purpose of this study is to see if adding an HIV vaccine (ALVAC-HIV vCP1452), IL-2 (interleukin-2, a protein found in the blood that helps boost the immune system), or both to anti-HIV-drug therapy is safe, tolerable, and effective in controlling viral load (level of HIV in the body). (This study has been changed to clarify drug name.) Anti-HIV drugs can help reduce a patient's viral load. However, HIV can still remain in CD4 cells (cells of the immune system that help fight infection). Combining an HIV vaccine, IL-2, or both with anti-HIV drugs may help reduce the number of HIV-infected cells.


Condition Intervention Phase
HIV Infections
Biological: ALVAC(2)120(B,MN)GNP (vCP1452)
Drug: Aldesleukin
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Partially Blinded Trial of Combinations of Potent Antiretroviral Therapy, HIV-Specific Immunizations, and Cycles of Interleukin-2 to Promote Efficient Control of Viral Replication

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment: 100
Study Completion Date: October 2005
Detailed Description:

The most important goal for designing future therapeutic interventions is to understand the nature of persistent HIV infection in patients successfully treated with potent antiretroviral therapy and to develop strategies to promote the clearance of these reservoirs or at least long-term suppression of these reservoirs. If latently infected cells are able to persist for a long period (despite effective suppression of de novo infection) primarily because immune clearance is not being adequately stimulated by viral antigen, then HIV-specific immunization is a reasonable strategy to enhance the clearance of these cells. Stimulating effective HIV-specific cellular immune responses at a time when plasma viremia is maximally suppressed also may contribute to the long-term containment of HIV replication on potent antiretroviral therapy. A second component to be evaluated in this trial is whether broad, cyclical activation of T cells with IL-2 will increase the activation of HIV proviral gene expression and thereby render target cells susceptible to immune-mediated clearance. This pathogenesis-based clinical trial will explore the potential for these novel treatment strategies (HIV-specific immunization and IL-2, alone and in combination) to complement the effects of potent antiretroviral therapy by promoting more effective immunologic control of HIV-1 replication.

This study is divided into 3 steps.

STEP I: Patients continue to receive their stable potent antiretroviral therapy and are randomized to 1 of 4 arms:

Arm A: Vaccine placebo [AS PER AMENDMENT 08/23/01: ALVAC]; Arm B: Canarypox HIV-specific immunogen [AS PER AMENDMENT 08/23/01: ALVAC-HIV] (vCP1452); Arm C: 8-week cycles of IL-2 plus vaccine placebo [AS PER AMENDMENT 08/23/01: ALVAC]; Arm D: 8-week cycles of IL-2 plus canarypox HIV-specific immunogen [AS PER AMENDMENT 08/23/01: ALVAC-HIV] (vCP1452).

Patients receive vaccine (or vaccine placebo) injections at Weeks 0, 8, 16, 24, and 48. IL-2 injections are synchronized with vaccine injections. IL-2 is given open-label while vCP1452 is double-blinded. Patients must be on Step I for a minimum of 51 weeks [AS PER AMENDMENT 08/23/01: prior to entry into Step II].

STEP II: Patients stop study medications and interrupt potent antiretroviral therapy for [AS PER AMENDMENT 08/23/01: "6 to 16" has been replaced by the following text: a minimum of 12] weeks. Patients whose viral load during Step II remains [AS PER AMENDMENT 08/23/01: at or] below 5,000 copies/ml [AS PER AMENDMENT 08/23/01: and whose CD4 count is 200 cells/mm3 or more] are encouraged to remain off antiretroviral medications and continue viral-load monitoring for up to an additional 10 weeks. These patients are followed [AS PER AMENDMENT 08/23/01: "for up to 16 weeks" has been replaced by the following text: through Week 74] on Step II and must register to Step III only if their viral load increases to 50,000 copies/ml or greater, their CD4 count decreases to below 200 cells/mm3, or if their primary care physician recommends resuming antiretrovirals.

STEP III: Patients resume their original potent antiretroviral therapy regimen for 6 to 10 weeks and are monitored for a minimum of 6 weeks. If patients do not achieve a viral load below 50 copies/ml during those 6 weeks, they continue to be monitored for up to an additional 4 weeks until this degree of suppression is achieved with the same potent antiretroviral therapy regimen or another appropriate regimen.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Patients may be eligible to enter this study if they:

  • Are HIV-positive.
  • Have taken the same anti-HIV drugs for at least 6 months prior to study entry. A change of 1 drug to another similar drug is allowed in certain cases.
  • Have a viral load of less than 50 copies/ml at screening and pre-entry. The measurements must be within 45 days of study entry.
  • Have a CD4 cell count of at least 350 cells/mm3 within 45 days prior to study entry.
  • Agree to use effective methods of birth control during the study and for 12 weeks after.

Exclusion Criteria

Patients may not be eligible for this study if they:

  • Have or have had an AIDS-related illness (except Kaposi's sarcoma or Pneumocystis carinii pneumonia).
  • Have had more than one potent antiretroviral regimen change due to virologic failure.
  • Have a history of autoimmune disease with the exception of stable autoimmune thyroid disease.
  • Have a history of allergy to eggs or other serious allergies.
  • Have serious heart problems. Patients with high blood pressure controlled by blood pressure medication but no heart disease may be eligible for this study.
  • Have cancer requiring chemotherapy.
  • Have untreated thyroid disease. Patients who are on treatment and stable for at least 4 weeks before study entry are eligible.
  • Have a serious central nervous system (CNS) disease or seizures, if these have been active within 1 year before study entry.
  • Require certain heart medications for angina or arrhythmia.
  • Are taking certain experimental anti-HIV drugs.
  • Are taking certain drugs that may interfere with their anti-HIV-drug combination.
  • Have taken drugs that might affect the immune system, within 4 weeks prior to study entry.
  • Have taken IL-2 before.
  • Have taken rifampin or rifabutin within 7 days before study entry if receiving indinavir.
  • Have received therapy for an infection or any serious medical illness within 30 days before study entry.
  • Have received immunizations within 30 days before study entry.
  • Have received any HIV vaccine during the past year or at any time while on their present anti-HIV therapy.
  • Work in close contact with canaries and are likely to have antibodies to the study vaccine prior to enrollment. (Patients with a pet canary may participate.)
  • Abuse alcohol or drugs or have mental or learning problems.
  • Are pregnant or breast-feeding.
  • Have received abacavir or hydroxyurea within 8 weeks prior to study entry.
  • Have a history of transplantation.
  • (This study has been changed to reflect added criteria.)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006291

  Hide Study Locations
Locations
United States, Alabama
Alabama Therapeutics CRS
Birmingham, Alabama, United States, 35294
United States, California
UCLA CARE Center CRS
Los Angeles, California, United States, 90095
USC CRS
Los Angeles, California, United States, 900331079
Stanford CRS
Palo Alto, California, United States, 943055107
Ucsf Aids Crs
San Francisco, California, United States, 94110
Santa Clara Valley Med. Ctr.
San Jose, California, United States, 951282699
San Mateo County AIDS Program
San Mateo, California, United States, 943055107
Marin County Dept. of Health & Human Services, HIV/AIDS Program & Specialty Clinic
San Rafael, California, United States
Harbor-UCLA Med. Ctr. CRS
Torrance, California, United States, 90502
United States, Colorado
University of Colorado Hospital CRS
Aurora, Colorado, United States, 80262
United States, Florida
Univ. of Miami AIDS CRS
Miami, Florida, United States, 331361013
United States, Georgia
The Ponce de Leon Ctr. CRS
Atlanta, Georgia, United States
United States, Hawaii
Univ. of Hawaii at Manoa, Leahi Hosp.
Honolulu, Hawaii, United States, 96816
United States, Illinois
Northwestern University CRS
Chicago, Illinois, United States, 60611
United States, Indiana
Indiana Univ. School of Medicine, Infectious Disease Research Clinic
Indianapolis, Indiana, United States, 462025250
Methodist Hosp. of Indiana
Indianapolis, Indiana, United States, 46202
Indiana Univ. School of Medicine, Wishard Memorial
Indianapolis, Indiana, United States, 46202
United States, Minnesota
University of Minnesota, ACTU
Minneapolis, Minnesota, United States, 55455
United States, New York
NY Univ. HIV/AIDS CRS
New York, New York, United States, 10016
Beth Israel Med. Ctr., ACTU
New York, New York, United States, 10003
Univ. of Rochester ACTG CRS
Rochester, New York, United States, 14642
United States, North Carolina
Unc Aids Crs
Chapel Hill, North Carolina, United States, 275997215
United States, Pennsylvania
Hosp. of the Univ. of Pennsylvania CRS
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
Vanderbilt Therapeutics CRS
Nashville, Tennessee, United States, 37203
United States, Texas
Univ. of Texas Medical Branch, ACTU
Galveston, Texas, United States, 775550435
Puerto Rico
Puerto Rico-AIDS CRS
San Juan, Puerto Rico, 009365067
Sponsors and Collaborators
Investigators
Study Chair: Michael Kilby
Study Chair: Ronald Mitsuyasu
  More Information

Additional Information:
No publications provided

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00006291     History of Changes
Other Study ID Numbers: A5024, 10070, ACTG A5024, AACTG A5024
Study First Received: September 22, 2000
Last Updated: May 17, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Virus Replication
T-Lymphocytes
Lymphocyte Transformation
AIDS Vaccines
Anti-HIV Agents
Viral Load
Aldesleukin
HIV Therapeutic Vaccine

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Aldesleukin
Interleukin-2
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on September 22, 2014